Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 50,407 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 1 Interventional

Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04384146
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cyclical Hypofractionated Palliative Radiation (Quad Shot), EORTC QLQ-C30 questionnaire
Radiation · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 1 Interventional

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946
View directory record Official record
Conditions
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Interventions
LTZ-301
Biological
Lead sponsor
LTZ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Duarte, California • St Louis, Missouri • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

NCT04342988
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cequa
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Laguna Hills, California • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT03564288
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
SKI-G-801
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Whittier, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

NCT01279603
View directory record Official record
Conditions
Solid Tumors
Interventions
GO-203-2c
Drug
Lead sponsor
Genus Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy

NCT00005903
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
GDNF & Synchro Med Infusion System
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

NCT03617003
View directory record Official record
Conditions
Upper Tract Urothelial Carcinoma
Interventions
WST11 mediated vascular targeted phototherapy (VTP), Endoscopy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
0 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fish Oil on Plasma Triglycerides in Adults

NCT00804427
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Fish oil (90% triglycerides), Fish oil (60% triglycerides), Fish oil (ethyl esters), Soy oil
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional

Dose Response Effects of Inhaled Fluticasone on Airway Effects of Hypertonic-saline in Asthma

NCT00606242
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 26, 2026, 2:46 PM EDT
Completed No phase listed Observational

PET Imaging in Patients at Risk for Acute Lung Injury

NCT01486342
View directory record Official record
Conditions
Acute Lung Injury, Early Pulmonary Neutrophilic Inflammation
Interventions
PET-CT scan
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 26, 2026, 2:46 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942
View directory record Official record
Conditions
Newly Diagnosed and Recurrent Glioblastoma
Interventions
[177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

NCT01774786
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 26, 2026, 2:46 PM EDT
Completed No phase listed Observational

Low Dose Irradiation for Small Bowel Transplant

NCT00382486
View directory record Official record
Conditions
Irreversible Intestinal Failure, Allograft Rejection
Interventions
Reduce the risk of allograft rejection
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
17 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2007 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)

NCT01523821
View directory record Official record
Conditions
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Interventions
Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 26, 2026, 2:46 PM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

NCT00338104
View directory record Official record
Conditions
Hyperglycemia, Diabetes
Interventions
insulin glargine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

NCT06105684
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine Pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease

NCT01049984
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rasagiline, Placebo
Drug
Lead sponsor
Teva Neuroscience, Inc.
Industry
Eligibility
30 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Fountain Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional Results available

A Study Of CP-690,550 In Stable Kidney Transplant Patients

NCT01710033
View directory record Official record
Conditions
Kidney Transplant
Interventions
Placebo, CP-690,550 5 mg BID, CP-690,550 15 mg BID, CP-690,550 30 mg BID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

NCT02287233
View directory record Official record
Conditions
Acute Myelogenous Leukemia, AML
Interventions
Venetoclax, Cytarabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
60 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
5
States / cities
Kansas City, Kansas • New York, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 26, 2026, 2:46 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean Delivery

NCT03877549
View directory record Official record
Conditions
Post Operative Pain
Interventions
Dexamethasone
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated Not applicable Interventional Results available

E-learning+ Rehab Therapy

NCT04245449
View directory record Official record
Conditions
Stroke
Interventions
TEAACH
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 26, 2026, 2:46 PM EDT